Tolerability of ketorolac administered via continuous subcutaneous infusion for cancer pain: a preliminary report.
We evaluated the local and systemic tolerability of ketorolac administered through continuous subcutaneous infusion in ten cancer patients. The patients were monitored daily for the severity and duration of pain, and the development of other symptoms. The duration of injection site varied from 1 to more than 7 days. No patients complained of local discomfort or pain. Mild local bleeding at the site of drug injection was observed in seven cases. No increase in the intensity of symptoms was observed during the infusion of ketorolac.
De Conno
F
F
Pain Therapy and Palliative Care Division, National Cancer Institute, Milan, Italy.
Zecca
E
E
Martini
C
C
Ripamonti
C
C
Caraceni
A
A
Saita
L
L
D000328:Adult; D000368:Aged; D000700:Analgesics / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D020910:Ketorolac; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications*; D010148:Intractable Pain / Q000188:drug therapy*; D013997:Time Factors; D014046:Tolmetin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*
D000700:Analgesics; D014046:Tolmetin; D020910:Ketorolac